[Translated article] N-acetylcysteine: 50 years since the discovery of an antidote that has changed the prognosis of acetaminophen poisoning [0.03%]
[N-乙酰半胱氨酸：发现改变急性对乙酰氨基酚中毒预后的解毒药五十周年]
Santiago Nogué-Xarau,Lidia Martínez-Sánchez,Milagros García-Peláez et al.
Santiago Nogué-Xarau et al.
Acetaminophen is one of the most widely used drugs in clinical practice due to its analgesic and antipyretic properties. However, overdose is one of the leading causes of severe acute liver failure. N-acetylcysteine, introduced as an antido...
Low-dose abiraterone acetate for the treatment of prostate cancer: An observational cohort study [0.03%]
低剂量阿比特龙治疗前列腺癌的疗效和安全性：前瞻性观察队列研究
Luis Angel Di-Giuseppe,Rodney Alexander Ramirez-Murillo,Mariano Daniel Aymar et al.
Luis Angel Di-Giuseppe et al.
Objective: To compare radiographic progression-free survival in metastatic prostate cancer patients treated with low-dose abiraterone versus standard-dose abiraterone acetate (Abi-SD), and to evaluate prostate-specific an...
Profile of clinical trials with drugs for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Spain [0.03%]
西班牙新冠病毒感染药物临床试验概况
Eduardo Tejedor-Tejada,Cristina González-Pérez,María Del Puy Goyache Goñi et al.
Eduardo Tejedor-Tejada et al.
Background: On 11 March 2020, World Health Organisation declared COVID-19 a pandemic. During the early stages, treatments lacking scientific evidence, such as hydroxychloroquine and later remdesivir, were used; meanwhile,...
Alemtuzumab in relapsing-remitting multiple sclerosis in clinical practice: Annual NEDA-3 follow-up for up to 4 years [0.03%]
临床实践中使用阿伦珠单抗治疗复发缓解型多发性硬化症的随访：长达四年的年NEDA-3跟踪调查
Leticia Herrero-Poch,Maria Susana Fortes-González,Antonio Pato-Pato et al.
Leticia Herrero-Poch et al.
Objective: The effectiveness of alemtuzumab in patients with relapsing-remitting multiple sclerosis (RRMS) have been demonstrated in clinical trials. The primary endpoint was to describe the annual effectiveness of alemtu...
Teresa Bermejo Vicedo,Maria Queralt Gorgas,Luis Margusino Framiñan
Teresa Bermejo Vicedo
Multidrug-resistant extra-pulmonary tuberculosis in a hemodyalisis patient treated with bedaquiline and tedizolid. A case report and a literature rewiew [0.03%]
一例血液透析患者的多重耐药性肺外结核病的贝达喹啉和泰地唑胺治疗：病例报告及文献回顾
Paula Novo González,Irene Galindo Marín,Elena García Benayas et al.
Paula Novo González et al.
[Translated article] Contribution of N-oxide metabolite in the therapeutic drug monitoring of voriconazole in a patient with invasive aspergillosis [0.03%]
曲霉病患者伏立康唑N-氧化代谢物对其治疗药物监测的贡献
Irene Orozco Cifuentes,Adrián Domínguez García,María Jiménez Meseguer et al.
Irene Orozco Cifuentes et al.
Desensitization protocol to pomalidomide in a patient with cutaneous hypersensitivity: A case report [0.03%]
来那度胺皮肤超敏反应患者的潘拉利珠单抗脱敏治疗：1例报告
Gabriel Martínez-Orea,Carlos Devesa-García,Laura Puente-Romero et al.
Gabriel Martínez-Orea et al.
Pomalidomide is a third-generation immunomodulatory drug that has been shown to be effective in the treatment of relapsed/refractory multiple myeloma. Although it is generally well tolerated, some patients may experience hypersensitivity re...
Reduction of unnecessary repackaging as an environmental sustainability measure [0.03%]
减少不必要的再包装作为环境可持续性措施
David García-Martínez,Manuela Martínez-Camacho,Aida Rueda-Naharro et al.
David García-Martínez et al.
Objective: The main objective is to describe the project and evaluate the impact of replacing repackaged medications with unit dose presentations in 15 public hospitals within a regional health system. Secondary objective...
Immunotherapy in advanced endometrial cancer with microsatellite instability: A systematic review [0.03%]
微卫星不稳定性子宫内膜癌免疫治疗的系统综述研究
Cristina Moreno-Ramos,Manuel David Gil-Sierra,María Del Pilar Briceño-Casado
Cristina Moreno-Ramos
Background: Endometrial cancer with microsatellite instability (MSI) involves 30% of diagnosed cases. There are some uncertainty about second-line treatment, after platinum-based first-line treatment. The aim of this stud...